{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T12:48:49Z","timestamp":1780836529964,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK069629"],"award-info":[{"award-number":["R01 DK069629"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jchromb.2023.123798","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T19:24:51Z","timestamp":1686425091000},"page":"123798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Characterization of binding by sulfonylureas with normal or modified human serum albumin using affinity microcolumns prepared by entrapment"],"prefix":"10.1016","volume":"1226","author":[{"given":"Saumen","family":"Poddar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley G.","family":"Woolfork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazia","family":"Iftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T.","family":"Ovbude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1145-5003","authenticated-orcid":false,"given":"David S.","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2023.123798_b0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0009-8981(85)90082-8","article-title":"Free drug measurements: methodology and clinical significance","volume":"151","author":"Kwong","year":"1985","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2023.123798_b0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2165\/00003088-199426010-00004","article-title":"Drug binding in plasma: a summary of recent trends in the study of drug and hormone binding","volume":"26","author":"Herve","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2023.123798_b0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0021-9673(00)00957-2","article-title":"Chromatographic and electrophoretic studies of protein binding to chiral solutes","volume":"906","author":"Hage","year":"2001","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2023.123798_b0020","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/c1ay05068k","article-title":"Chromatographic analysis of drug interactions in the serum proteome","volume":"3","author":"Hage","year":"2011","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jchromb.2023.123798_b0025","series-title":"All About Albumin: Biochemistry, Genetics, and Medical Applications","author":"Peters","year":"1995"},{"key":"10.1016\/j.jchromb.2023.123798_b0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1248\/bpb.25.695","article-title":"Practical aspects of the ligand-binding and enzymatic properties of human serum albumin","volume":"25","author":"Kragh-Hansen","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jchromb.2023.123798_b0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/358209a0","article-title":"Atomic structure and chemistry of human serum albumin","volume":"358","author":"He","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2023.123798_b0040","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0026-895X(25)10691-3","article-title":"The characterization of two specific drug binding sites on human serum albumin","volume":"11","author":"Sudlow","year":"1975","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123798_b0045","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0026-895X(25)10855-9","article-title":"Further characterization of specific drug binding sites on human serum albumin","volume":"12","author":"Sudlow","year":"1976","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123798_b0050","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1021\/ac9903499","article-title":"Characterization of minor site probes for human serum albumin by high-performance affinity chromatography","volume":"71","author":"Sengupta","year":"1999","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2023.123798_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0378-4347(98)00589-1","article-title":"Characterisation of the binding of digitoxin and acetyldigitoxin to human serum albumin by high-performance affinity chromatography","volume":"724","author":"Hage","year":"1999","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cca.2013.07.013","article-title":"Review: Glycation of human serum albumin","volume":"425","author":"Anguizola","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2023.123798_b0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1515\/revac-2013-0029","article-title":"Studies of drug interactions with glycated human serum albumin by high-performance affinity chromatography","volume":"33","author":"Matsuda","year":"2014","journal-title":"Rev. Anal. Chem"},{"key":"10.1016\/j.jchromb.2023.123798_b0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.saa.2017.05.023","article-title":"Alteration of human serum albumin binding properties induced by modifications: a review","volume":"188","author":"Maciazek-Jurczyk","year":"2018","journal-title":"Spectrochim Acta Part A: Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jchromb.2023.123798_b0075","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2174\/1381612821666150302115025","article-title":"Review: modifications of human serum albumin and their binding effect","volume":"21","author":"Lee","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jchromb.2023.123798_b0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1753-0407.2010.00104.x","article-title":"Compating the global diabetes epidemic","volume":"3","author":"Kozak","year":"2011","journal-title":"J. Diabetes"},{"key":"10.1016\/j.jchromb.2023.123798_b0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/pop.2015.0181","article-title":"Diabetes 2030: Insights from yesterday, today, and future trends","volume":"20","author":"Rowley","year":"2017","journal-title":"Popul. Health Manag."},{"key":"10.1016\/j.jchromb.2023.123798_b0090","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehm486","article-title":"Clinical and prognostic value of advanced glycation end-products in chronic heart failure","volume":"28","author":"Hartog","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jchromb.2023.123798_b0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mem.2001.114314","article-title":"Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment","volume":"38","author":"Harrigan","year":"2001","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.jchromb.2023.123798_b0100","doi-asserted-by":"crossref","unstructured":"M.J. Crooks, K.F. Brown, Binding of sulfonylureas to serum albumin, J. Pharm. Pharmacol. 26 (1974) 304-311.","DOI":"10.1111\/j.2042-7158.1974.tb09280.x"},{"key":"10.1016\/j.jchromb.2023.123798_b0105","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/jps.2600621147","article-title":"Binding of sulfonylureas to serum albumin. Comments","volume":"62","author":"Crooks","year":"1973","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.jchromb.2023.123798_b0110","first-page":"75","article-title":"Binding of sulfonylureas to serum albumin. II. Influence of salt and buffer compositions on tolbutamide and glyburide","volume":"9","author":"Brown","year":"1974","journal-title":"Can. J. Pharmaceut. Sci."},{"key":"10.1016\/j.jchromb.2023.123798_b0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0006-2952(75)90294-4","article-title":"Interaction of glipizide with human serum albumin","volume":"24","author":"Crooks","year":"1975","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123798_b0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.chroma.2015.09.023","article-title":"Analysis of drug-protein binding using on-line immunoextraction and high-performance affinity microcolumns: studies with normal and glycated human serum albumin","volume":"1416","author":"Matsuda","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2023.123798_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461683","article-title":"Studies of binding by sulfonylureas with glyoxal- and methylglyoxal-modified albumin by immunoextraction using affinity microcolumns","volume":"1638","author":"Rodriguez","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2023.123798_b0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ab.2010.05.004","article-title":"Entrapment of proteins in glycogen-capped and hydrazide-activated supports","volume":"404","author":"Jackson","year":"2010","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2023.123798_b0135","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchromb.2015.11.021","article-title":"Entrapment of alpha1-acid glycoprotein in high-performance affinity columns for drug-protein binding studies","volume":"1021","author":"Bi","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2019.05.004","article-title":"Optimization of protein entrapment in affinity microcolumns using hydrazide-activated silica and glycogen as a capping agent","volume":"1121","author":"Vargas-Badilla","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jchromb.2014.01.026","article-title":"Analysis of biomolecular interactions using affinity microcolumns: a review","volume":"968","author":"Zheng","year":"2014","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0150","series-title":"Analysis of Drug-Protein Interactions during Diabetes by High-Performance Affinity Chromatography","author":"Tao","year":"2019"},{"key":"10.1016\/j.jchromb.2023.123798_b0155","series-title":"Advanced Separation Methods for the Analysis of Drugs and Other Targets by High-Performance Liquid Chromatography","author":"Woolfork","year":"2021"},{"key":"10.1016\/j.jchromb.2023.123798_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114097","article-title":"High-performance affinity chromatographic studies of repaglinide and nateglinide interactions with normal and glyoxal- or methylglyoxal-modified human albumin serum","volume":"201","author":"Ovbude","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123798_b0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1515\/DMDI.2008.23.1-2.125","article-title":"Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease","volume":"23","author":"Thornalley","year":"2008","journal-title":"Drug Metab. Drug Interact."},{"key":"10.1016\/j.jchromb.2023.123798_b0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0009-2797(97)00157-9","article-title":"Glutathione-dependent detoxification of \u03b1-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors","volume":"111\u2013112","author":"Thornalley","year":"1998","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jchromb.2023.123798_b0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0006-2952(00)00287-2","article-title":"Kinetics and mechanism of the reaction of aminoguanidine with the \u03b1-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions","volume":"60","author":"Thornalley","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123798_b0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ab.2019.02.014","article-title":"Determination of glyoxal and methylglyoxal in serum by UHPLC coupled with fluorescence detection","volume":"573","author":"Dhananjayan","year":"2019","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2023.123798_b0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0003-2697(81)90547-9","article-title":"A fluorimetric assay for available lysine in proteins","volume":"115","author":"Goodno","year":"1981","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2023.123798_b0190","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1021\/ac303734c","article-title":"Development of affinity microcolumns for drug-protein binding studies in personalized medicine: interactions of sulfonylurea drugs with in vivo glycated human serum albumin","volume":"85","author":"Anguizola","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2023.123798_b0195","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0003-2697(78)90029-5","article-title":"A sensitive fluorometric method for the determination of arginine using 9,10-phenanthrenequinone","volume":"90","author":"Smith","year":"1978","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2023.123798_b0200","series-title":"Analysis of the Metabolic Effects of Diabetes on the Function and Structure of Modified Human Serum Albumin","author":"Ovbude","year":"2022"},{"key":"10.1016\/j.jchromb.2023.123798_b0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0021-9673(94)80332-3","article-title":"Development of dihydrazide-activated silica supports for high-performance affinity chromatography","volume":"669","author":"Ruhn","year":"1994","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2023.123798_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121812","article-title":"Development of an on-line immunoextraction\/entrapment system for protein capture and use in drug binding studies by high-performance affinity chromatography","volume":"1136","author":"Rodriguez","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0215","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1007\/s00216-016-9677-7","article-title":"On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography","volume":"408","author":"Anguizola","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2023.123798_b0220","series-title":"Applications of High Performance Affinity Chromatography with High Capacity Stationary Phases Made by Entrapment","author":"Vargas-Badilla","year":"2015"},{"key":"10.1016\/j.jchromb.2023.123798_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2022.340629","article-title":"Preparation of entrapment-based microcolumns for analysis of drug-humic acid interactions by high-performance affinity chromatography","volume":"1239","author":"Iftekhar","year":"2023","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jchromb.2023.123798_b0230","series-title":"Handbook of Affinity Chromatography","first-page":"595","article-title":"Quantitative affinity chromatography: practical aspects","author":"Hage","year":"2005"},{"key":"10.1016\/j.jchromb.2023.123798_b0235","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/ac00093a043","article-title":"Chiral separation mechanisms in protein-based HPLC columns. I. Thermodynamic studies of R- and S-warfarin binding to immobilized human serum albumin","volume":"66","author":"Loun","year":"1994","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2023.123798_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123500","article-title":"Analysis of the binding of warfarin to glyoxal- and methylglyoxal-modified human serum albumin by ultrafast affinity extraction","volume":"1211","author":"Iftekhar","year":"2022","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2018.01.020","article-title":"Analysis of solute-protein interactions and solute-solute competition by zonal elution affinity chromatography","volume":"146","author":"Tao","year":"2018","journal-title":"Methods"},{"key":"10.1016\/j.jchromb.2023.123798_b0250","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.jchromb.2010.08.021","article-title":"Chromatographic analysis of acetohexamide binding to glycated human serum albumin","volume":"878","author":"Joseph","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0255","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jchromb.2018.09.001","article-title":"Chromatographic studies of chlorpropamide interactions with normal and glycated human serum albumin based on affinity microcolumns","volume":"1097\u20131098","author":"Tao","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2023.123798_b0260","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpba.2019.01.025","article-title":"Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography","volume":"166","author":"Tao","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123798_b0265","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpba.2010.09.003","article-title":"Binding of tolbutamide to glycated human serum albumin","volume":"54","author":"Joseph","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123798_b0270","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00216-011-5382-8","article-title":"High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin","volume":"401","author":"Matsuda","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2023.123798_b0275","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1007\/s00216-015-8688-0","article-title":"Analysis of glipizide binding to normal and glycated human serum albumin by high-performance affinity chromatography","volume":"407","author":"Matsuda","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2023.123798_b0280","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.chroma.2012.09.091","article-title":"Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycated human serum albumin","volume":"1265","author":"Matsuda","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2023.123798_b0285","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1007\/s00216-013-6981-3","article-title":"Use of entrapment and high-performance affinity chromatography to compare the binding of drugs and site-specific probes with normal and glycated human serum albumin","volume":"405","author":"Jackson","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2023.123798_b0290","series-title":"Handbook of Affinity Chromatography","first-page":"35","article-title":"Immobilizaton methods for affinity chromatography","author":"Kim","year":"2005"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223002088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223002088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:11:56Z","timestamp":1761606716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223002088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":58,"alternative-id":["S1570023223002088"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123798","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of binding by sulfonylureas with normal or modified human serum albumin using affinity microcolumns prepared by entrapment","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123798"}}